ARPA-H highlighted efforts to reduce the cold-chain burden of biologics by funding BioStabilization Systems (BoSS), a program aimed at storing certain cell and gene therapy products at room temperature. The work targets the logistical fragility of cryopreservation, where freeze-thaw cycles and shipping disruptions can jeopardize product viability. The agency described CAR T cells and other thermally unstable biologics as part of a broader challenge affecting both cost and risk, noting that each dose can accrue substantial handling expenses and that lost products translate into lost clinical opportunity. BoSS is designed around nature-inspired preservation strategies, with aims that could simplify logistics for therapies that currently require liquid nitrogen shipping. If successful, the approach could reshape how hospitals and CDMOs plan manufacturing-to-site distribution and reduce dependence on tightly controlled storage conditions.